> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA to Study Adherence Effect on Promotion
- URL: https://www.fdaweb.com/fda-to-study-adherence-effect-on-promotion/
- Published: 2023-10-12T12:00:00.000Z
- Updated: 2026-09-14T19:02:22.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5155546

The CDER Office of Prescription Drug Promotion is planning to research how claims that appeal to the possibility for greater adherence or to social norms around what other patients or healthcare providers influence perceptions of a drug. A *Federal Register* [notice](https://www.govinfo.gov/content/pkg/FR-2023-10-12/pdf/2023-22586.pdf?ref=fdaweb.com) says a related question is whether including a disclosure stating the uncertainty around such claims can mitigate any misleading perceptions or influence preferences.

The notice says the specific research questions are:

- whether the presence or absence of an implied adherence claims affects consumers’ behavioral intentions or risk, benefit, and adherence perceptions;
- whether the presence or absence of an adherence-related patient preference claim affects consumers’ behavioral intentions or risk, benefit, and adherence perceptions;
- whether the presence of both adherence and preference claims have a cumulative impact on consumers’ behavioral intentions or risk, benefit, and adherence perceptions; and
- whether a disclosure of information to the effect that there is no conclusive research on whether the drug results in better adherence mitigates consumers’ behavioral intentions or risk, benefit, and adherence perceptions.

Comments on the proposed research will be accepted until 12/11.